Regulus Therapeutics (RGLS) Q2 Revenue Tops Views

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), may not compare to the analyst estimate of ($0.29). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $2.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• BofA lists top 5 themes driving next $1tn in incremental semi sales